Biotechnology Advances Submission Process

The current ScienceDirect journal page gives several process-relevant signals that authors should keep separate from Manusights interpretation:

In our pre-submission review work with Biotechnology Advances packages, we read the submission process as one connected object: abstract, article type, cover letter, figure sequence, supplement labels, author metadata, declarations, suggested reviewers, and the first claim the editor will see in Editorial Manager. The manuscript may be scientifically competent and still be process-weak if those pieces point to different stories.

Coverage without a process thesis. We often see reviews that have enough references, a long table, and a broad title, but no sentence that tells the editor what position the review takes. In the upload workflow, that is not a style problem. It makes the editor's routing job harder because no reviewer pool is obvious. The fix is to make the review thesis visible in the title, abstract, Figure 1, and cover letter before the record is submitted.

Application pathway hidden in the last third. Biotechnology Advances is indexed and searched as a high-impact applied-biotechnology venue, and the current ScienceDirect page shows a 12.5 Impact Factor and 24.6 CiteScore. A manuscript that waits until the discussion to explain industrial, therapeutic, environmental, agricultural, or platform relevance forces the editor to read like a detective. We flag this as a process risk because it changes the first decision, not only the final paper quality.

Authorship and declarations treated as cleanup. Elsevier's author guide says the author list and submission-system details matter at original submission, and post-submission authorship changes are generally not considered. When we see unsettled author order, missing CRediT roles, vague competing-interest statements, or a data statement that does not match the supplement, we treat the package as not ready for the portal even if the review argument is strong.

Sister-venue ambiguity. The paper can be good and still not belong in this workflow. A shorter opinion piece may fit Trends in Biotechnology, a topical snapshot may fit Current Opinion in Biotechnology, and primary method or bioprocess data may fit Journal of Biotechnology, Metabolic Engineering, Bioresource Technology, or another specialist title better. The process page exists because authors need to make that routing call before a fast Elsevier decision makes it for them.

ScienceDirect currently lists journal-level medians of about 9 days to first decision, 52 days to decision after review, 130 days to acceptance, and 3 days from acceptance to online publication. Those numbers are useful because they show the first screen is fast. They are not a guarantee. A strong review article can take longer if reviewer recruitment is hard, and a weak-fit manuscript can leave the process quickly.

The process starts before you click submit. Biotechnology Advances is not only checking whether files can be uploaded. The editor is checking whether the package tells one applied-biotechnology story.

Before opening the record, have these pieces ready:

• manuscript file with article type, title, abstract, figures, tables, references, and source coverage aligned
• cover letter that states the biotechnology synthesis argument, not only the topic
• author list and order confirmed with all affiliations and emails
• conflict-of-interest, funding, ethics, data availability, and author-contribution statements
• suggested reviewers who understand both the biotechnology domain and the application pathway
• supplementary files labeled so the editor and reviewers can see what each file supports
• graphical abstract or main schematic that explains the review's organizing argument, not only its scope

The official guide warns that authorship changes after submission are generally not considered. That makes the author list a process issue. Do not use the submission record to settle authorship. Confirm order, corresponding-author responsibility, and institutional details before upload.

The first check is administrative but not trivial. Elsevier and the journal need a record that can be handled without policy confusion.

Typical early checks include:

• author names in the manuscript matching the submission-system entries
• author order and corresponding-author details final enough for the record
• conflict-of-interest, funding, ethics, and data-availability declarations present
• manuscript and supplementary files opening correctly
• figures and tables labeled clearly
• suggested reviewers entered with enough expertise context
• cover letter present and tied to Biotechnology Advances rather than a generic journal pitch

A common process mistake is to treat these as clerical fields. At Biotechnology Advances, metadata and files also shape triage. If the title says "advances in X," the abstract reads like a neutral survey, the cover letter says "comprehensive review," and the figure package has no application-pathway schematic, the record is administratively complete but editorially hard to send out.

The first editorial screen asks whether the manuscript deserves external review as a Biotechnology Advances paper. For this journal, that means the editor is not only checking novelty. The editor is checking whether the manuscript has a synthesis claim and an applied-biotechnology pathway.

The strongest packages make these signals agree:

The editor can return a paper quickly if the record reads like a bibliography rather than a review with judgment. For planning, treat 1 to 14 days as a normal editorial-triage range, with complex or ambiguous scope cases taking longer when reviewer fit, article type, or transfer routing is unclear. That is why the process page is commercially useful: the upload sequence is not hard, but the first screen is expensive to misunderstand.

A fast first decision at Biotechnology Advances is usually an editorial-triage outcome. It does not mean the paper received full peer review in a few days.

Read the status path:

• Submitted to With Editor to Decision: likely editor triage, administrative return, scope return, or transfer consideration.
• Submitted to Under Review to Decision: more likely external review or reviewer invitation plus editor synthesis.
• With Editor for several weeks: possible reviewer matching, scope uncertainty, or editor availability.
• Under Review for several months: reviewer invitation, active review, delayed report, or editor synthesis.

The most useful response to a fast return is not to resubmit immediately. First identify whether the decision was about scope, synthesis, article type, missing declarations, authorship, or a better Elsevier transfer route.

If the manuscript is sent out, reviewers are usually checking more than factual coverage. Biotechnology Advances reviews are expected to help readers judge where a biotechnology field is going and what is viable.

Elsevier's guide describes Biotechnology Advances as using a single-anonymized peer review process, with editor assessment before suitable submissions are typically sent to at least two independent reviewers. For authors, that means the manuscript does not need anonymized-file preparation for double-blind review, but the author record, conflicts, suggested reviewers, and application logic must still survive editor and reviewer scrutiny.

Reviewers often test:

• whether the review takes a defensible position rather than summarizing papers chronologically
• whether the application pathway is real: industrial, environmental, agricultural, therapeutic, regulatory, or platform-facing
• whether scale, benchmark, cost, deployment, or translational constraints are acknowledged
• whether the figures and tables synthesize the field rather than decorate the manuscript
• whether the source coverage is current, balanced, and not limited to one lab or approach
• whether the article fits Biotechnology Advances better than Trends in Biotechnology, Current Opinion in Biotechnology, Journal of Biotechnology, Metabolic Engineering, or a specialist venue

The paper can be scientifically sound and still draw a hard revision if it does not organize the field for a practicing biotechnologist.

Elsevier's Article Transfer Service can matter after a decline. A transfer offer is not a failure by itself. It may save time if the receiving journal fits the manuscript better. It is a mistake only when authors accept a transfer without checking whether the new journal's readership actually matches the paper.

In Manusights pre-submission work on Biotechnology Advances packages, we see four process failures before the scientific debate starts.

• Coverage without a thesis: the editor sees topic breadth but no position the review will defend.
• Application pathway as decoration: the biotechnology use case appears after the evidence instead of organizing it.
• Authorship and declarations as admin: author order, contributions, competing interests, ethics statement, and data availability statement are still unstable when the record opens.
• Sibling-venue ambiguity: the paper is real scholarship but better suited to a trend, opinion, method, or specialist research venue.

The review has coverage but no thesis

The manuscript lists recent papers, organizes them by subtopic, and calls the result comprehensive. That can look complete in the upload record, but it gives the editor no reason to spend reviewer time. The process fix is to make the thesis visible in the abstract, Figure 1, section order, and cover letter.

The application pathway is decorative

The paper mentions industrial, therapeutic, environmental, or agricultural relevance, but the evidence does not show how the field moves toward use. Biotechnology Advances readers need the practical pathway to be load-bearing. A sentence in the conclusion is not enough.

The author and declaration record is treated as admin

Elsevier's author guide makes authorship details and post-submission changes a real process constraint. If the author list, contributions, funding, conflicts, or data statements are still unsettled, the manuscript is not process-ready even if the science is mature.

The paper is a better fit for a sibling venue

Some manuscripts are strong but wrong for this process. A shorter trend article may fit Trends in Biotechnology. A topical view may fit Current Opinion in Biotechnology. A research article centered on method development may fit Journal of Biotechnology, Metabolic Engineering, or a specialist biotechnology journal. The process can fail because the first editor sees the wrong audience.

Check whether your Biotechnology Advances review has a real thesis →

Check whether your application pathway is visible before upload →

Check whether your author and declaration record is complete →

This guide tells you what the process tests before and after Editorial Manager submission. The review tells you whether your paper passes that process screen before the upload becomes the editor's first impression. Manusights reviews are read by multiple expert reviewers, include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Last verified July 2026 against ScienceDirect author guidance, the ScienceDirect journal page, Elsevier Editorial Manager routing, and the current Manusights Biotechnology Advances cluster. Publisher instructions, portal fields, and timing medians can change, so use official Elsevier pages for the live upload record.